enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Tezepelumab - Wikipedia

   en.wikipedia.org/wiki/Tezepelumab

   Tezepelumab, sold under the brand name Tezspire, is a human monoclonal antibody used for the treatment of asthma. [5] [7] [8] [9] Tezepelumab blocks thymic stromal lymphopoietin (TSLP), [5] an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation.

3. AstraZeneca gets FDA breakthrough therapy label for asthma ...

   www.aol.com/news/astrazeneca-gets-fda...

   The drug, tezepelumab, is an injectable treatment that is expected to help a wider range of patients than existing asthma medicines like GlaxoSmithKline's (GSK.L) Nucala. A breakthrough therapy ...

4. AstraZeneca's Asthma Drug Gets Breakthrough Therapy Status - AOL

   www.aol.com/news/astrazeneca-apos-asthma-drug...

   AstraZeneca (AZN) and partner Amgen's asthma candidate, tezepelumab gets Breakthrough Therapy designation from the FDA.

5. Cromoglicic acid - Wikipedia

   en.wikipedia.org/wiki/Cromoglicic_acid

   It is considered a breakthrough drug in management of asthma, as the patients can be freed from steroids in many cases; however, it is mainly effective as a prophylaxis for allergic and exercise-induced asthma, not as a treatment for acute asthma attacks. [citation needed]

6. Ligelizumab - Wikipedia

   en.wikipedia.org/wiki/Ligelizumab

   Ligelizumab (INN; development code QGE031) is a humanized IgG1 monoclonal antibody designed for the treatment of severe asthma and chronic spontaneous urticaria. [1] It is an anti-IgE that binds to IGHE an acts as an immunomodulator. [2] [3] It is delivered as a subcutaneous biologic injection. [4] This drug was developed by Novartis Pharma AG.

7. List of drugs granted breakthrough therapy designation

   en.wikipedia.org/wiki/List_of_drugs_granted...

   Treatment of people aged 12 years of age and older with solid tumors that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy [2]